Enveric Biosciences’ EVM301 Portfolio Receives Five Additional US Patents

Overview

Enveric Biosciences, a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, announces the expansion of patent protection for a broad range of molecules in its EVM301 portfolio through the issuance of five additional US patents and the recent allowance of three more patent applications by the United States Patent and Trademark Office.

EVM301 Addiotional Patents 

• The US Patent Nos. 11,845,727; 11,858,895; 11,891,359; 11,998,557 and 12,128,058 join four other patents previously announced, bringing the total to nine issued US patents covering the EVM301 portfolio and its drug candidate library. 
• Enveric’s Psybrary is a proprietary catalogue of over 1,000 tryptamine derivative molecules that incorporates receptor engagement and functional data to correlate structure with biological activity.

Words from the CEO: Enveric

• The increasing depth and breadth of the EVM301 portfolio of molecules with strong intellectual property backing expands the value-capture opportunities available to Enveric,” said Dr. Joseph Tucker, CEO of Enveric. 
• The EVM301 portfolio extends across a broad range of tryptamine derivative molecules including, but not limited to, carboxylated, aminated, prenylated, glycosylated, nitrilated, and halogenated derivative molecules, and combinations of two or more of these functional motifs, in the form of multi-substituent tryptamine derivatives.
• Enveric’s drug discovery engine has also uncovered molecules demonstrating enhanced preference for 5-HT2C receptors. “Included in our portfolio are several molecules, protected by issued patent claims, with potential as antiepileptic and anti-obesity drug candidates, which have demonstrated enhanced binding preference for the 5-HT2C receptor relative to other serotonergic, dopaminergic, and adrenergic receptor targets,” reported Dr. Tucker.

About EB-003: the Compound

• The lead candidate derived from the EVM301 Series of compounds, EB-003, which targets major undertreated mental health indications including treatment-resistant depression and anxiety, is currently in preclinical development to support filing an Investigational New Drug (IND) application in 2025. 
• The favourable safety profile of EB-003 is supported by receptor engagement data with key serotonergic targets that suggest the ability to promote clinically important neuroplasticity without inducing hallucinations, a significant safety concern limiting the potential to reach patients.

About the Company

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!